Viking Therapeutics Reports Clinical Progress and Financial Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy VKTX?
Source: PRnewswire
Viking Therapeutics Inc. saw its stock surge by 18.18% as it reached a 5-day high, reflecting positive market sentiment following recent financial and clinical updates.
The company reported a significant increase in R&D expenses for Q4 2025, totaling $153.5 million, driven by ongoing clinical trials for its obesity treatment VK2735. Despite a widening net loss of $157.7 million, Viking's completion of enrollment for the VANQUISH-1 trial and progress towards the VANQUISH-2 trial indicate strong commitment to advancing its drug pipeline. This strategic focus on obesity treatment is expected to enhance market recognition and potential revenue.
With a cash reserve of $706 million, Viking is well-positioned to support its R&D activities and navigate the financial challenges posed by increased expenditures. The company's proactive approach in clinical development and market strategy suggests a promising outlook for its obesity treatment initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.610
Low
70.00
Averages
97.00
High
125.00
Current: 33.610
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Shows Potential Amid Risks in AI Bubble
- Market Potential: Viking Therapeutics has an average price target of $92.72, indicating an upside of approximately 181% from current levels, reflecting optimistic market expectations for its future performance.
- Clinical Trial Progress: The company is conducting pivotal trials for VK2735, with results expected next year, which will directly impact its competitive position in the rapidly growing weight-loss drug market.
- Product Development Updates: Viking Therapeutics plans to advance an oral version of VK2735 into phase 3 studies in Q3, which, if successful, will further enhance its market competitiveness.
- Risks and Opportunities: While there is significant upside potential, the company must demonstrate competitive efficacy and tolerability in phase 3 trials; otherwise, its stock price may face downward pressure.
See More
Viking Plans to Advance VK2735 Oral Drug
- Clinical Trial Progress: Viking Therapeutics is set to advance its experimental oral obesity drug VK2735 into late-stage studies in Q3 2026, with plans for four late-stage trials by the end of 2026, indicating a proactive approach in the obesity treatment sector.
- Expected Drug Efficacy: The subcutaneous formulation of VK2735 demonstrated a mean weight loss of 14.7% over 13 weeks in mid-stage trials, with the CEO expressing hopes that it will be competitive with existing GLP-1 monoagonists, thereby enhancing market competitiveness.
- Market Competition Analysis: Unlike industry giants Novo Nordisk and Eli Lilly, which launched subcutaneous forms of their blockbuster obesity drugs first, Viking's strategy to develop both subcutaneous and oral formulations showcases its diversified approach in the obesity drug market, especially as Novo's oral drug launched in January.
- New Drug Application Plans: Viking is also looking to file an application to initiate trials for a novel amylin agonist this quarter, aiming to expand its obesity portfolio and further strengthen its market position in this therapeutic area.
See More
VKTX Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: VKTX's 52-week low is $18.92 per share, while the high is $43.15, with the last trade at $31.51, indicating significant volatility in its stock price over the past year, reflecting varying market expectations for its future performance.
- Technical Indicator Observation: The current price of $31.51 is below its 52-week high, which may suggest a cautious market sentiment, prompting investors to monitor whether it will break through the 200-day moving average to gauge future trends.
- Market Sentiment Assessment: Despite experiencing considerable fluctuations over the past year, VKTX's current price remains above its low point, indicating a degree of market confidence, and investors should closely watch relevant market dynamics.
- Investor Focus: VKTX's stock performance is closely tied to its fundamentals and market trends, and investors should pay attention to the company's upcoming financial reports and industry news to make more informed investment decisions.
See More
Viking Therapeutics to Participate in Investor Conferences
- Investor Conference Participation: Viking Therapeutics announced its participation in multiple upcoming investor conferences, aiming to enhance its visibility and attractiveness in the capital markets through live webcasts showcasing its latest developments.
- Clinical Trial Progress: The company is conducting Phase 3 clinical trials for VK2735, including VANQUISH-1 and VANQUISH-2, with early trials demonstrating a favorable safety and tolerability profile, potentially laying the groundwork for future market launches.
- New Drug Development Achievements: VK2809 successfully met both primary and secondary endpoints in a Phase 2 trial, showing significant effects in treating non-alcoholic fatty liver disease (NAFLD) and lowering LDL-C, thereby strengthening the company's competitive position in the metabolic disease sector.
- Rare Disease Treatment Exploration: Viking is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD), which demonstrated good safety in a Phase 1 trial while significantly reducing plasma levels of very long-chain fatty acids, showcasing its potential market value.
See More
Viking Therapeutics: A Major Player in the Weight Loss Arena
Current Market Dynamics: The pharmaceutical industry is experiencing a significant shift with a demand for new players to disrupt the dominance of established companies like Novo Nordisk and Eli Lilly in obesity treatments, creating opportunities for agile competitors like Viking Therapeutics.
Viking's Competitive Edge: Viking Therapeutics has emerged as a leading challenger in the obesity treatment market, with its primary asset, VK2735, showing promising results in clinical trials, including significant weight loss outcomes.
Strategic Developments: Viking is strategically positioning itself for potential acquisition while simultaneously building its infrastructure for independent operations, highlighted by recent key appointments and partnerships to enhance its manufacturing capabilities.
Investment Outlook: Despite current losses and skepticism in the market, Viking's strong cash reserves and advanced clinical data present a compelling investment opportunity, with analysts suggesting significant upside potential if the company successfully executes its roadmap.
See More
Eli Lilly Strengthens Lead in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly currently holds a 60% share of the U.S. weight loss drug market, surpassing Novo Nordisk's offerings, demonstrating strong competitiveness in this rapidly growing sector and likely driving further revenue growth.
- Clinical Trial Advantage: In the latest clinical trial, Lilly's Zepbound helped patients lose over 25% of their weight over 84 weeks, compared to only 23% for Novo's CagriSema, indicating superior efficacy and solidifying its market leadership.
- Convenience Enhancement: Lilly's newly released Zepbound format holds a month's worth of doses in a single pen, improving medication convenience for patients, especially while traveling, which is expected to enhance patient adherence and market appeal.
- Broad Market Outlook: Analysts expect the weight loss drug market to reach nearly $100 billion over the next four years, with Lilly's new drug orforglipron and other potential products poised to drive further growth, despite facing challenges from competitors like Novo Nordisk.
See More
Viking Therapeutics Shows Potential Amid Risks in AI Bubble
- Market Potential: Viking Therapeutics has an average price target of $92.72, indicating an upside of approximately 181% from current levels, reflecting optimistic market expectations for its future performance.
- Clinical Trial Progress: The company is conducting pivotal trials for VK2735, with results expected next year, which will directly impact its competitive position in the rapidly growing weight-loss drug market.
- Product Development Updates: Viking Therapeutics plans to advance an oral version of VK2735 into phase 3 studies in Q3, which, if successful, will further enhance its market competitiveness.
- Risks and Opportunities: While there is significant upside potential, the company must demonstrate competitive efficacy and tolerability in phase 3 trials; otherwise, its stock price may face downward pressure.
See More
Viking Plans to Advance VK2735 Oral Drug
- Clinical Trial Progress: Viking Therapeutics is set to advance its experimental oral obesity drug VK2735 into late-stage studies in Q3 2026, with plans for four late-stage trials by the end of 2026, indicating a proactive approach in the obesity treatment sector.
- Expected Drug Efficacy: The subcutaneous formulation of VK2735 demonstrated a mean weight loss of 14.7% over 13 weeks in mid-stage trials, with the CEO expressing hopes that it will be competitive with existing GLP-1 monoagonists, thereby enhancing market competitiveness.
- Market Competition Analysis: Unlike industry giants Novo Nordisk and Eli Lilly, which launched subcutaneous forms of their blockbuster obesity drugs first, Viking's strategy to develop both subcutaneous and oral formulations showcases its diversified approach in the obesity drug market, especially as Novo's oral drug launched in January.
- New Drug Application Plans: Viking is also looking to file an application to initiate trials for a novel amylin agonist this quarter, aiming to expand its obesity portfolio and further strengthen its market position in this therapeutic area.
See More
VKTX Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: VKTX's 52-week low is $18.92 per share, while the high is $43.15, with the last trade at $31.51, indicating significant volatility in its stock price over the past year, reflecting varying market expectations for its future performance.
- Technical Indicator Observation: The current price of $31.51 is below its 52-week high, which may suggest a cautious market sentiment, prompting investors to monitor whether it will break through the 200-day moving average to gauge future trends.
- Market Sentiment Assessment: Despite experiencing considerable fluctuations over the past year, VKTX's current price remains above its low point, indicating a degree of market confidence, and investors should closely watch relevant market dynamics.
- Investor Focus: VKTX's stock performance is closely tied to its fundamentals and market trends, and investors should pay attention to the company's upcoming financial reports and industry news to make more informed investment decisions.
See More
Viking Therapeutics to Participate in Investor Conferences
- Investor Conference Participation: Viking Therapeutics announced its participation in multiple upcoming investor conferences, aiming to enhance its visibility and attractiveness in the capital markets through live webcasts showcasing its latest developments.
- Clinical Trial Progress: The company is conducting Phase 3 clinical trials for VK2735, including VANQUISH-1 and VANQUISH-2, with early trials demonstrating a favorable safety and tolerability profile, potentially laying the groundwork for future market launches.
- New Drug Development Achievements: VK2809 successfully met both primary and secondary endpoints in a Phase 2 trial, showing significant effects in treating non-alcoholic fatty liver disease (NAFLD) and lowering LDL-C, thereby strengthening the company's competitive position in the metabolic disease sector.
- Rare Disease Treatment Exploration: Viking is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD), which demonstrated good safety in a Phase 1 trial while significantly reducing plasma levels of very long-chain fatty acids, showcasing its potential market value.
See More
Viking Therapeutics: A Major Player in the Weight Loss Arena
Current Market Dynamics: The pharmaceutical industry is experiencing a significant shift with a demand for new players to disrupt the dominance of established companies like Novo Nordisk and Eli Lilly in obesity treatments, creating opportunities for agile competitors like Viking Therapeutics.
Viking's Competitive Edge: Viking Therapeutics has emerged as a leading challenger in the obesity treatment market, with its primary asset, VK2735, showing promising results in clinical trials, including significant weight loss outcomes.
Strategic Developments: Viking is strategically positioning itself for potential acquisition while simultaneously building its infrastructure for independent operations, highlighted by recent key appointments and partnerships to enhance its manufacturing capabilities.
Investment Outlook: Despite current losses and skepticism in the market, Viking's strong cash reserves and advanced clinical data present a compelling investment opportunity, with analysts suggesting significant upside potential if the company successfully executes its roadmap.
See More
Eli Lilly Strengthens Lead in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly currently holds a 60% share of the U.S. weight loss drug market, surpassing Novo Nordisk's offerings, demonstrating strong competitiveness in this rapidly growing sector and likely driving further revenue growth.
- Clinical Trial Advantage: In the latest clinical trial, Lilly's Zepbound helped patients lose over 25% of their weight over 84 weeks, compared to only 23% for Novo's CagriSema, indicating superior efficacy and solidifying its market leadership.
- Convenience Enhancement: Lilly's newly released Zepbound format holds a month's worth of doses in a single pen, improving medication convenience for patients, especially while traveling, which is expected to enhance patient adherence and market appeal.
- Broad Market Outlook: Analysts expect the weight loss drug market to reach nearly $100 billion over the next four years, with Lilly's new drug orforglipron and other potential products poised to drive further growth, despite facing challenges from competitors like Novo Nordisk.
See More
